Johnson & Johnson $JNJ Shares Acquired by CoreCap Advisors LLC

CoreCap Advisors LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 6.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,078 shares of the company’s stock after buying an additional 3,157 shares during the period. CoreCap Advisors LLC’s holdings in Johnson & Johnson were worth $13,523,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Outlook Capital Management LLC bought a new position in shares of Johnson & Johnson during the second quarter worth about $28,000. Matrix Trust Co lifted its position in Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares during the last quarter. Montgomery Financial Services LLC acquired a new position in Johnson & Johnson during the 2nd quarter valued at about $43,000. Hyposwiss Advisors SA bought a new position in Johnson & Johnson in the 4th quarter worth about $42,000. Finally, Polaris Financial Partners bought a new position in Johnson & Johnson in the 3rd quarter worth about $56,000. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer Taubert sold 15,000 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares in the company, valued at approximately $4,367,458. The trade was a 48.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 87,569 shares of company stock worth $23,064,544. Corporate insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of a number of recent analyst reports. Wells Fargo & Company lifted their price target on Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. UBS Group restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, September 22nd. JPMorgan Chase & Co. lifted their target price on Johnson & Johnson from $270.00 to $285.00 and gave the company a “neutral” rating in a research note on Tuesday, September 29th. Freedom Capital upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. Finally, Guggenheim reissued a “buy” rating and set a $287.00 price target on shares of Johnson & Johnson in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $276.22.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Strong earnings setup: Analysts are focused on JNJ’s September-quarter revenue, earnings, pharmaceutical growth and operating performance. The company has a history of exceeding estimates, while its latest quarter showed 6.6% year-over-year revenue growth and adjusted EPS above consensus. JNJ’s full-year 2026 EPS outlook is $11.60-$11.75. Johnson & Johnson Q3 earnings preview
• Positive Sentiment: Pipeline could support faster growth: Positive longer-term data for ICOTYDE in psoriasis and encouraging Phase 3 multiple-myeloma results for the Tecvayli-Talvey combination strengthen the case that JNJ can generate growth beyond its traditional defensive profile. Johnson & Johnson long-term growth outlook
• Positive Sentiment: Analyst and dividend support: Guggenheim reaffirmed a Buy rating with a $287 price target, while other coverage continues to highlight JNJ’s 64-year record of dividend increases. The company is viewed as offering more dependable cash generation than higher-yielding but financially weaker peers. Johnson & Johnson dividend outlook
• Neutral Sentiment: Valuation reflects quality: Commentary comparing JNJ with Pfizer argues that JNJ commands a higher earnings multiple because its earnings outlook is more stable and potentially stronger. That premium may support the shares, but it also leaves less room for disappointment if quarterly results or guidance fall short. Johnson & Johnson valuation comparison
• Negative Sentiment: Key risks remain: Investors continue to monitor biosimilar competition, slower MedTech growth and ongoing talc litigation. These issues could pressure future pharmaceutical sales, margins or investor confidence despite the company’s dividend record. Johnson & Johnson risks and dividend analysis

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded down $1.60 during trading on Thursday, reaching $256.85. The company had a trading volume of 6,146,800 shares, compared to its average volume of 7,971,840. The firm’s fifty day moving average is $265.71 and its 200 day moving average is $248.78. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The firm has a market capitalization of $618.99 billion, a PE ratio of 29.76, a price-to-earnings-growth ratio of 2.50 and a beta of 0.21. Johnson & Johnson has a twelve month low of $184.66 and a twelve month high of $281.07.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter last year, the business earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.54 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson’s payout ratio is currently 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.